Expected Outcome:
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all the following expected outcomes:
Scope:
Mental, behavioural and neurodevelopmental disorders, that include for example severe depression, anxiety, schizophrenia, psychosis, post-traumatic stress disorder (PTSD), addictive behaviours (drugs[3], alcohol, gaming and others), obsessive-compulsive disorder, eating disorders and autism spectrum disorder are a high burden for patients, health systems and society, and remain unmet medical needs. More innovative, safer and more effective therapeutic and relapse-preventing solutions based on active substances are required, as for example for mental disorders many available treatments show modest efficacy, non-negligible side effects, discontinuation problems and high relapse rates. Additionally, other non-invasive multidisciplinary and/or transdiagnostic approaches (e.g. neurostimulation, neuroimaging, digital, non-pharmaceutical, psychotherapy, psychosocial) should be further developed to complement the therapeutic and relapse prevention solutions. These approaches aim to further improve health outcomes, self-determination, autonomy and quality of life in the long-term.
The disorders within the scope of this topic fall under Chapter 6 of the International Classification of Diseases[4]. Rare diseases are excluded[5].
Proposals should address most of the following aspects:
The participation of start-ups, micro, small and medium-sized enterprises (SMEs)[13] is encouraged with the aim of strengthening their scientific and technological foundations, enhancing their innovation potential, and exploring possibilities for commercial exploitation.
Funded projects should liaise with the European Partnership for Brain Health (covered by topic HORIZON-HLTH-2025-02-DISEASE-01) once launched.
The topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.
All projects funded under this topic are strongly encouraged to participate in networking and joint activities, as appropriate. Therefore, proposals should include a budget for the attendance to regular joint meetings and may consider covering the costs of any other potential joint activities without the prerequisite to detail concrete joint activities at this stage. The details of these joint activities will be defined during the grant agreement preparation phase.
Applicants invited to the second stage should provide details of their clinical studies[14] in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.
The EC is impact-driven: proposals must show how the project will:
Solve a major European or global societal challenge
Deliver measurable, lasting benefits for EU citizens
Produce outputs that can be used by policymakers, industry, or society
Align with Horizon Europe missions, priorities, and strategic agendas
Predictor: Clear, quantifiable, EU-level impact → strongest scoring factor.
Successful proposals show:
2–4 well-defined objectives linked to the Work Programme call text
Clearly articulated research questions or innovation goals
Logical, realistic expected outcomes and deliverables
Feasible scientific and technical approaches
Predictor: Balanced ambition + feasibility.
For RIA/IA/CSA or ERC-level grants, reviewers expect:
High novelty and innovation
Strong grounding in current state-of-the-art
Clear advancement beyond existing approaches
Solid theoretical or experimental foundations
Robust methodological design
Predictor: Scientific excellence is essential for competitive scoring.
EC proposals are consortium-driven (except ERC/EIC Accelerator).
High-scoring consortia:
Cover all needed competencies (science, industry, policy, ethics, dissemination)
Include SMEs, industry partners, NGOs, and public bodies when relevant
Are geographically diverse across EU Member States and Associated Countries
Demonstrate strong leadership and communication structures
Predictor: Well-constructed consortium with clear roles.
Evaluators look for a credible trajectory showing:
How research leads to specific outputs (data, tools, prototypes)
How outputs lead to uptake or use
How use produces societal, economic, scientific, or policy impact
Strong Key Performance Indicators (KPIs) and impact metrics
Predictor: Clearly mapped impact pathway.
Winning proposals have:
Well-designed Work Packages (WPs) with clear scope and responsibilities
Interdependencies identified and risk-mitigation strategies
Detailed milestones and deliverables
Feasible budget aligned with tasks
Strong project management plan
Predictor: High implementation quality boosts the “Excellence” and “Implementation” scores.
Especially critical for health, climate, digital, and social calls.
Proposals score higher when they link to:
EU Cancer Mission
EU Green Deal
Digital Europe strategy
EU Biodiversity Strategy
EU Health Union & One Health
Open Science & FAIR data mandates
Predictor: Clear alignment with EU policies.
EC values inclusivity:
Patient groups
Civil society organizations
Public sector bodies
Regulatory agencies
Citizen science components
Stakeholder letters of intent or commitment strengthen credibility.
Predictor: Engagement adds impact and relevance.
Mandatory components include:
FAIR Data Management Plan
Open access publications
Ethics self-assessment
GDPR compliance
Data security, governance, and ethical approvals
Animal-use reduction and justification (if applicable)
Predictor: Clear compliance with ethical and data obligations.
Budget must be:
Proportional to tasks
Transparent and reasonable
Efficiently distributed among partners
Free from padding or unjustified costs
Predictor: Realistic budgets improve Implementation scores.
| Pitfall | Why It Fails |
|---|---|
| Weak connection to Work Programme text | Immediate score reduction |
| Vague or generic impact statements | Poor Impact score |
| Overly ambitious, unrealistic scope | Feasibility concerns |
| Poorly structured consortium | Low Implementation score |
| No policy relevance | Weak strategic alignment |
| Lack of concrete KPIs or outcomes | Impact unclear |
| Weak data or ethics plan | Eligibility/score penalties |
| No exploitation or dissemination plan | Insufficient impact credibility |
| Budget misalignment | Reviewer distrust |
Eligible Countries
Eligible Countries are described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
Other Eligible Conditions
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
The following exceptions apply: subject to restrictions for the protection of European communication networks.
Sponsor Institute/Organizations: European Commission
Sponsor Type: Corporate/Non-Profit
Address: Rue de la Loi 200 / Wetstraat 200, 1049 Brussels, Belgium.
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Apr 16, 2026
Apr 16, 2026
$9,440,000
Affiliation: European Commission
Address: Rue de la Loi 200 / Wetstraat 200, 1049 Brussels, Belgium.
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.